EUVIMEDEUVIMED entdecken
Open Access

Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection

Edward T Qian, Jonathan D Casey, Adam Wright, Li Wang, Matthew S Shotwell, Justin K Siemann, Mary Lynn Dear, Joanna L Stollings, Brad D Lloyd, Tanya K Marvi, Kevin P Seitz, George E Nelson und 10 weitere

JAMA · 24.10.2023 · 330 (16) · 1557

DOI: 10.1001/jama.2023.20583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 24.10.2023. Verfasst von Edward T Qian und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Sepsis, Acute Kidney Injury, Delirium. Die Arbeit wurde bisher 156-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS, NCRR NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Cefepime and piperacillin-tazobactam are commonly administered to hospitalized adults for empirical treatment of infection. Although piperacillin-tazobactam has been hypothesized to cause acute kidney injury and cefepime has been hypothesized to cause neurological dysfunction, their comparative safety has not been evaluated in a randomized clinical trial.

Objective

To determine whether the choice between cefepime and piperacillin-tazobactam affects the risks of acute kidney injury or neurological dysfunction. Design, Setting, and Participants The Antibiotic Choice on Renal Outcomes (ACORN) randomized clinical trial compared cefepime vs piperacillin-tazobactam in adults for whom a clinician initiated an order for antipseudomonal antibiotics within 12 hours of presentation to the hospital in the emergency department or medical intensive care unit at an academic medical center in the US between November 10, 2021, and October 7, 2022. The final date of follow-up was November 4, 2022.

Interventions

Patients were randomized in a 1:1 ratio to cefepime or piperacillin-tazobactam. Main Outcomes and Measures The primary outcome was the highest stage of acute kidney injury or death by day 14, measured on a 5-level ordinal scale ranging from no acute kidney injury to death. The 2 secondary outcomes were the incidence of major adverse kidney events at day 14 and the number of days alive and free of delirium and coma within 14 days.

Results

There were 2511 patients included in the primary analysis (median age, 58 years [IQR, 43-69 years]; 42.7% were female; 16.3% were Non-Hispanic Black; 5.4% were Hispanic; 94.7% were enrolled in the emergency department; and 77.2% were receiving vancomycin at enrollment). The highest stage of acute kidney injury or death was not significantly different between the cefepime group and the piperacillin-tazobactam group; there were 85 patients (n = 1214; 7.0%) in the cefepime group with stage 3 acute kidney injury and 92 (7.6%) who died vs 97 patients (n = 1297; 7.5%) in the piperacillin-tazobactam group with stage 3 acute kidney injury and 78 (6.0%) who died (odds ratio, 0.95 [95% CI, 0.80 to 1.13], P = .56). The incidence of major adverse kidney events at day 14 did not differ between groups (124 patients [10.2%] in the cefepime group vs 114 patients [8.8%] in the piperacillin-tazobactam group; absolute difference, 1.4% [95% CI, −1.0% to 3.8%]). Patients in the cefepime group experienced fewer days alive and free of delirium and coma within 14 days (mean [SD], 11.9 [4.6] days vs 12.2 [4.3] days in the piperacillin-tazobactam group; odds ratio, 0.79 [95% CI, 0.65 to 0.95]). Conclusions and Relevance Among hospitalized adults in this randomized clinical trial, treatment with piperacillin-tazobactam did not increase the incidence of acute kidney injury or death. Treatment with cefepime resulted in more neurological dysfunction. Trial Registration ClinicalTrials.gov Identifier: NCT05094154

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SepsisAcute Kidney InjuryDeliriumHumansAdultFemaleMiddle AgedMaleAnti-Bacterial AgentsCefepimeComaPiperacillinDrug Therapy, CombinationRetrospective StudiesPiperacillin, Tazobactam Drug CombinationKidney

Substanzen

Anti-Bacterial AgentsCefepimePiperacillinPiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Bioinformatics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Division of General Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Biostatistics, School of Medicine, Vanderbilt University, Nashville, Tennessee.
  • Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee.

Förderung

  • AHRQ HHS
  • NCRR NIH HHS
  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NCATS NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Qian, E. T., Casey, J. D., Wright, A., Wang, L., Shotwell, M. S., Siemann, J. K., Dear, M. L., Stollings, J. L., Lloyd, B. D., Marvi, T. K., Seitz, K. P., Nelson, G. E., Wright, P. W., Siew, E. D., Dennis, B. M., Wrenn, J. O., Andereck, J. W., Han, J. H., Self, W. H., …, & Vanderbilt Center for Learning Healthcare and the Pragmatic Critical Care Research Group (2023). Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection. JAMA, 330(16), 1557. https://doi.org/10.1001/jama.2023.20583

Vancouver

Qian ET, Casey JD, Wright A, Wang L, Shotwell MS, Siemann JK, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection. JAMA. 2023;330(16):1557. doi:10.1001/jama.2023.20583

BibTeX
@article{Qian2023,
  author = {Qian, Edward T and Casey, Jonathan D and Wright, Adam and Wang, Li and Shotwell, Matthew S and Siemann, Justin K and Dear, Mary Lynn and Stollings, Joanna L and Lloyd, Brad D and Marvi, Tanya K and Seitz, Kevin P and Nelson, George E and Wright, Patty W and Siew, Edward D and Dennis, Bradley M and Wrenn, Jesse O and Andereck, Jonathan W and Han, Jin H and Self, Wesley H and Semler, Matthew W and Rice, Todd W and Vanderbilt Center for Learning Healthcare and the Pragmatic Critical Care Research Group, Vanderbilt Center for Learning Healthcare and the Pragmatic Critical Care Research Group},
  title = {Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {16},
  pages = {1557},
  doi = {10.1001/jama.2023.20583}
}
Kostenlos starten →